Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Manuela Giachelia, Maria Teresa Voso, Maria Chiara Tisi, Maurizio Martini, Valentina Bozzoli, Giuseppina Massini, Francesco D'Alo', Luigi Maria Larocca, Giuseppe Leone, Stefan Hohaus
Entra nei temi di ricerca di 'Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.'. Insieme formano una fingerprint unica.